Organization
College of Medicine, University of Cincinnati
1 abstract
Abstract
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).Org: College of Medicine, University of Cincinnati, Wexner Medical Center and The James Cancer Hospital, Ohio State University, Women's Cancer Care Associates, Arizona Oncology Associates, Texas Oncology - Fort Worth Cancer Center,